[go: up one dir, main page]

IL187676A0 - Serum-free stable transfection and production of recombinant human proteins in human cell lines - Google Patents

Serum-free stable transfection and production of recombinant human proteins in human cell lines

Info

Publication number
IL187676A0
IL187676A0 IL187676A IL18767607A IL187676A0 IL 187676 A0 IL187676 A0 IL 187676A0 IL 187676 A IL187676 A IL 187676A IL 18767607 A IL18767607 A IL 18767607A IL 187676 A0 IL187676 A0 IL 187676A0
Authority
IL
Israel
Prior art keywords
serum
production
cell lines
stable transfection
free stable
Prior art date
Application number
IL187676A
Other versions
IL187676A (en
Original Assignee
Octagene Gmbh
Octapharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35427852&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL187676(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Octagene Gmbh, Octapharma Ag filed Critical Octagene Gmbh
Publication of IL187676A0 publication Critical patent/IL187676A0/en
Publication of IL187676A publication Critical patent/IL187676A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10Cells modified by introduction of foreign genetic material
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/505Erythropoietin [EPO]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/53Colony-stimulating factor [CSF]
    • C07K14/535Granulocyte CSF; Granulocyte-macrophage CSF
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • C07K14/755Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81Protease inhibitors
    • C07K14/8107Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121Serpins
    • C07K14/8125Alpha-1-antitrypsin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67General methods for enhancing the expression
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • C12N9/6427Chymotrypsins (3.4.21.1; 3.4.21.2); Trypsin (3.4.21.4)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • C12N9/6437Coagulation factor VIIa (3.4.21.21)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • C12N9/644Coagulation factor IXa (3.4.21.22)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/02Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21001Chymotrypsin (3.4.21.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21021Coagulation factor VIIa (3.4.21.21)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21022Coagulation factor IXa (3.4.21.22)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/90Serum-free medium, which may still contain naturally-sourced components
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00Genetically modified cells
    • C12N2510/04Immortalised cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/10Plasmid DNA
    • C12N2800/106Plasmid DNA for vertebrates
    • C12N2800/107Plasmid DNA for vertebrates for mammalian
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2820/00Vectors comprising a special origin of replication system
    • C12N2820/007Vectors comprising a special origin of replication system tissue or cell-specific
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2820/00Vectors comprising a special origin of replication system
    • C12N2820/60Vectors comprising a special origin of replication system from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
IL187676A 2005-06-30 2007-11-27 Serum-free stable transfection and production of recombinant human proteins in human cell lines IL187676A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05105965A EP1739179A1 (en) 2005-06-30 2005-06-30 Serum-free stable transfection and production of recombinant human proteins in human cell lines
PCT/EP2006/063705 WO2007003582A2 (en) 2005-06-30 2006-06-29 Serum-free stable transfection and production of recombinant human proteins in human cell lines

Publications (2)

Publication Number Publication Date
IL187676A0 true IL187676A0 (en) 2008-08-07
IL187676A IL187676A (en) 2017-02-28

Family

ID=35427852

Family Applications (3)

Application Number Title Priority Date Filing Date
IL266122A IL266122B2 (en) 2005-06-30 2006-06-29 Serum-free stable transfection and production of recombinant human proteins in human cell lines
IL187676A IL187676A (en) 2005-06-30 2007-11-27 Serum-free stable transfection and production of recombinant human proteins in human cell lines
IL250575A IL250575A0 (en) 2005-06-30 2017-02-13 Serum-free stable transfection and production of recombinant human proteins in human cell lines

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL266122A IL266122B2 (en) 2005-06-30 2006-06-29 Serum-free stable transfection and production of recombinant human proteins in human cell lines

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL250575A IL250575A0 (en) 2005-06-30 2017-02-13 Serum-free stable transfection and production of recombinant human proteins in human cell lines

Country Status (20)

Country Link
US (4) US8871439B2 (en)
EP (2) EP1739179A1 (en)
JP (3) JP5925407B2 (en)
KR (1) KR101320489B1 (en)
CN (2) CN101233238A (en)
AU (1) AU2006265173B2 (en)
BR (1) BRPI0613721B1 (en)
CA (1) CA2611708C (en)
DK (1) DK1896590T3 (en)
ES (1) ES2574584T3 (en)
HU (1) HUE028028T2 (en)
IL (3) IL266122B2 (en)
MX (1) MX2007015370A (en)
NO (1) NO343221B1 (en)
PL (1) PL1896590T3 (en)
RU (1) RU2453597C2 (en)
SI (1) SI1896590T1 (en)
UA (1) UA99700C2 (en)
WO (1) WO2007003582A2 (en)
ZA (1) ZA200711013B (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2164971B1 (en) * 2007-06-15 2015-12-09 Mogam Biotechnology Research Institute Method for manufacturing active recombinant blood coagulation factor ix
AU2009264282B2 (en) 2008-06-24 2013-04-18 Octapharma Ag A process of purifying coagulation factor VIII
EP2331569A1 (en) * 2008-08-21 2011-06-15 Octapharma AG Recombinantly produced human factor viii and ix
JP5592080B2 (en) * 2009-05-08 2014-09-17 株式会社日立製作所 Cell culture method and cell culture system
CN101906438B (en) * 2009-06-05 2013-04-24 苏州泽璟生物制药有限公司 Method for expressing and producing recombinant human blood coagulation factors VII in animal cells
KR101808751B1 (en) 2009-11-13 2017-12-13 그리폴스 테라퓨틱스 인코포레이티드 VON WILLEBRAND FACTOR (vWF)-CONTAINING PREPARATIONS, AND METHODS, KITS, AND USES RELATED THERETO
BR112012024956A2 (en) 2010-03-30 2016-07-12 Octapharma Ag process for purifying a growth factor protein
JP5876868B2 (en) 2010-03-30 2016-03-02 オクタファルマ・アーゲー Method for purifying vitamin K-dependent protein such as IX coagulation factor
WO2011131720A1 (en) 2010-04-20 2011-10-27 Octapharma Ag New stabilizing agent for pharmaceutical proteins
CN103517919B (en) 2011-05-13 2016-11-16 欧克塔医药公司 The method improving eukaryotic cell productivity ratio in the production of restructuring FVIII
CN102277379B (en) * 2011-08-18 2013-07-24 中国科学院遗传与发育生物学研究所 Expression vector for expressing coagulation factor VIII and application thereof
CN103031277B (en) * 2011-09-29 2015-07-15 重庆大学 Application of mechano-growth factor in preparation of serum-free cultured tolerant type mammal engineering cell
CN103305540B (en) * 2012-03-14 2015-03-25 齐鲁制药有限公司 Plasmid for determination of biological activity and preparation method thereof
CA3051089C (en) 2012-05-02 2022-04-12 Life Technologies Corporation High yield transient expression in mammalian cells using unique pairing of high density growth and transfection medium and expression enhancers
ES2732907T3 (en) * 2013-05-03 2019-11-26 Fujifilm Diosynth Biotechnologies Uk Ltd Expression Procedure
LT3044231T (en) * 2013-09-12 2020-11-10 Biomarin Pharmaceutical Inc. Aav vectors comprising a gene encoding factor viii
EP3097118B1 (en) 2014-01-20 2018-07-18 Octapharma AG A process for manufacturing factor viii having an improved ratio of fviii:c/fviii:ag
CA2966527C (en) 2014-11-02 2024-02-06 Arcturus Therapeutics, Inc. Messenger una molecules and uses thereof
EP3625329A1 (en) 2017-05-17 2020-03-25 Octapharma AG Method for the production of a recombinant target protein
JP7150056B2 (en) 2018-05-04 2022-10-07 フラウンホーファー-ゲゼルシャフト ツール フエルデルング デア アンゲヴァンテン フォルシュング エー.ファオ. Arterial spin labeling method with evaluation of magnetization reversal state
WO2020115318A1 (en) * 2018-12-06 2020-06-11 Basf Se Aqueous suspension comprising a zeolitic material and a zirconium chelate complex
CN110438066B (en) * 2019-08-19 2021-01-12 杭州百凌生物科技有限公司 Mammalian cell line 293C18P capable of being stably passaged and capable of being cultured in suspension, and preparation method and application thereof

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU577259B2 (en) * 1982-08-13 1988-09-22 Zymogenetics Inc. Glycolytic promters for regulated protein expression protease inhibitor
US4540573A (en) 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
ATE224445T1 (en) 1984-01-12 2002-10-15 Chiron Corp DNA SEQUENCES CODING FOR FACTOR VIIIC AND RELATED DNA CONSTRUCTIONS
IL74909A (en) 1984-04-20 1992-01-15 Genentech Inc Preparation of functional human factor viii and dna sequences,expression vectors,transformed microorganisms and cell lines used therein
JPS6171774A (en) 1984-09-14 1986-04-12 Sony Corp Beam current controller of television camera device
US4868112A (en) 1985-04-12 1989-09-19 Genetics Institute, Inc. Novel procoagulant proteins
JPS63500636A (en) * 1985-08-23 1988-03-10 麒麟麦酒株式会社 DNA encoding multipotent granulocyte colony stimulating factor
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
EP0253870B1 (en) 1986-01-03 1993-03-31 Genetics Institute, Inc. Method for producing factor viii:c-type proteins
FI98829C (en) 1986-01-27 1997-08-25 Chiron Corp Process for Preparation of Recombinant Protein Complex with Human Factor VIII: C Activity
US5451521A (en) 1986-05-29 1995-09-19 Genetics Institute, Inc. Procoagulant proteins
EP0251843A1 (en) 1986-06-06 1988-01-07 Transgene S.A. Process for the preparation of factor VIII from mammalian cells
DK155388C (en) 1986-07-08 1989-10-23 Palle Pedersen LOCK
ATE63335T1 (en) 1986-07-11 1991-05-15 Miles Inc PRODUCTION OF RECOMBINANT PROTEIN.
NO872932L (en) 1986-07-18 1988-01-19 Gist Brocades Nv PROCEDURE FOR THE MANUFACTURE OF PROTEINS WITH FACTOR VIVILITY BY MICROBIAL HOSTS, EXPRESSING VECTORS, HOSTING CELLS, ANTIBIOTICS.
IL84168A0 (en) 1986-10-15 1988-03-31 Rorer Int Overseas Human factor viii-c analogs,process for the preparation thereof and pharmaceutical compositions containing the same
EP0294910B1 (en) 1987-06-12 1996-09-11 Immuno Ag Novel proteins with factor VIII activity, process for their preparation using genetically engineered cells and pharmaceutical compositions containing them
FR2619314B1 (en) 1987-08-11 1990-06-15 Transgene Sa FACTOR VIII ANALOG, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME
JPH084495B2 (en) * 1988-08-19 1996-01-24 帝人株式会社 Method for culturing adherent animal cells
HUT70457A (en) 1989-11-17 1995-10-30 Chiron Corp Protein complexes having factor viii:c activity and production thereof
SE465222C5 (en) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab A recombinant human factor VIII derivative and process for its preparation
DE4204694C3 (en) 1992-02-01 1995-10-12 Octapharma Ag Method for obtaining highly pure, virus-inactivated factor VIII by means of anion exchange chromatography
CA2155337A1 (en) 1993-02-09 1994-08-18 Monika Stadler Method for inactivating viruses devoid of lipid envelopes
US5585237A (en) * 1993-10-25 1996-12-17 Creative Biomolecules, Inc. Methods and compositions for high protein production from recombinant DNA
DK128093D0 (en) 1993-11-12 1993-11-12 Novo Nordisk As HIS UNKNOWN RELATIONSHIPS
US6136865A (en) 1995-05-20 2000-10-24 Octapharma Ag Method for reduction of the infectiousness of potentially infectious material
JP2002517180A (en) * 1997-12-05 2002-06-18 ジ・イミユーン・リスポンス・コーポレーシヨン Novel vectors and genes exhibiting increased expression
CZ20003842A3 (en) * 1998-04-17 2001-08-15 Société des Produits Nestlé S. A. Cellular line of human keratinocytes
US6210924B1 (en) * 1998-08-11 2001-04-03 Amgen Inc. Overexpressing cyclin D 1 in a eukaryotic cell line
CA2252972C (en) * 1998-11-26 2012-09-18 National Research Council Of Canada Serum-free production of recombinant proteins and adenoviral vectors
EP1010762A1 (en) 1998-12-02 2000-06-21 Aventis Behring Gesellschaft mit beschränkter Haftung DNA constructs of blood clotting factors and P-Selectin
PT1161548E (en) 1999-04-15 2005-06-30 Crucell Holland Bv PRODUCTION OF RECOMBINANT PROTEINS IN A HUMAN CELL USING SEQUENCES BY CODING ADENOVIRUS E1 PROTEIN
CA2407714A1 (en) * 1999-04-29 2000-11-09 Leukotech A/S Expression of heparin-binding protein in recombinant mammalian cells
EP1210411B1 (en) * 1999-08-25 2006-10-18 Immunex Corporation Compositions and methods for improved cell culture
DE60115613T2 (en) 2000-03-22 2006-08-24 Octagene Gmbh PREPARATION OF RECOMBINANT MOUTHES OF BLOOD CREATING FACTOR VIII IN HUMAN CELL LINES
KR20030024799A (en) * 2000-07-20 2003-03-26 뉴로젠 코포레이션 Capsaicin receptor ligands
WO2002099089A1 (en) * 2001-06-04 2002-12-12 Corixa Corporation Compositions and methods for high-level, large-scale production of recombinant proteins
US20040180438A1 (en) * 2002-04-26 2004-09-16 Pachuk Catherine J. Methods and compositions for silencing genes without inducing toxicity
DE50308030D1 (en) 2002-11-29 2007-10-04 Boehringer Ingelheim Pharma NEW NEOMYCIN PHOSPHOTRANSFERASE GENES AND METHOD FOR SELECTION OF HIGHLY PRODUCTIVE RECOMBINANT CELLS
US7217566B2 (en) 2003-03-24 2007-05-15 Invitrogen Corporation Attached cell lines
US7763430B2 (en) * 2003-04-22 2010-07-27 Baxter International Inc. Diagnostic assay for anti-von Willebrand Factor cleaving protease (ADAMTS13) antibodies
KR101435167B1 (en) * 2003-06-27 2014-11-04 암젠 프레몬트 인코포레이티드 Deletion mutant-directed antibodies of epithelial growth factor receptor and uses thereof
JP2005073509A (en) * 2003-08-28 2005-03-24 Nihon Pharmaceutical Co Ltd Method for producing human antithrombin
CA2540135C (en) * 2003-10-03 2012-12-04 Keiichi Fukuda Method of inducing the differentiation of stem cells into cardiomyocytes
JP4705473B2 (en) * 2003-11-06 2011-06-22 株式会社リプロセル Stem cell cryopreservation method and system
EA200600918A1 (en) * 2003-11-06 2006-10-27 Игзонхит Терапьютикс Са VASE455, THE OPTION OF ALTERNATIVE SPLICING BETA-SECRETASE OF A MAN
BRPI0908886A2 (en) 2008-02-15 2015-09-15 Koninkl Philips Electronics Nv device, method and computer program for segmenting an object, and, object model

Also Published As

Publication number Publication date
IL187676A (en) 2017-02-28
IL266122B2 (en) 2025-07-01
HUE028028T2 (en) 2016-11-28
SI1896590T1 (en) 2016-07-29
EP1896590A2 (en) 2008-03-12
RU2453597C2 (en) 2012-06-20
BRPI0613721A2 (en) 2011-02-08
WO2007003582A3 (en) 2007-05-18
US20150044720A1 (en) 2015-02-12
ES2574584T3 (en) 2016-06-20
WO2007003582A2 (en) 2007-01-11
JP2019058173A (en) 2019-04-18
KR101320489B1 (en) 2013-10-30
CN105755041A (en) 2016-07-13
US20160177362A1 (en) 2016-06-23
DK1896590T3 (en) 2016-06-13
PL1896590T3 (en) 2016-10-31
CN101233238A (en) 2008-07-30
IL250575A0 (en) 2017-03-30
CA2611708A1 (en) 2007-01-11
UA99700C2 (en) 2012-09-25
RU2008103319A (en) 2009-08-10
JP5925407B2 (en) 2016-05-25
US20170152523A1 (en) 2017-06-01
ZA200711013B (en) 2008-10-29
US9273325B2 (en) 2016-03-01
JP2008544750A (en) 2008-12-11
JP6754414B2 (en) 2020-09-09
NO20076087L (en) 2008-01-28
BRPI0613721B1 (en) 2022-05-24
EP1896590B1 (en) 2016-03-23
US8871439B2 (en) 2014-10-28
JP2016154537A (en) 2016-09-01
AU2006265173B2 (en) 2011-07-28
US9512457B2 (en) 2016-12-06
IL266122B1 (en) 2025-03-01
IL266122A (en) 2019-06-30
US20100184141A1 (en) 2010-07-22
MX2007015370A (en) 2008-02-11
KR20080028891A (en) 2008-04-02
NO343221B1 (en) 2018-12-10
CA2611708C (en) 2019-11-12
EP1739179A1 (en) 2007-01-03
AU2006265173A1 (en) 2007-01-11
US9796986B2 (en) 2017-10-24

Similar Documents

Publication Publication Date Title
IL250575A0 (en) Serum-free stable transfection and production of recombinant human proteins in human cell lines
PT2506857T (en) Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases
IL262205A (en) Protein formulations and methods of making same
EP2102355A4 (en) Long acting proteins and peptides and methods of making and using the same
ZA200906061B (en) Use of copper and glutamate in cell culture for production of polypeptides
SG10201404308RA (en) Recombinant human epo-fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
EP2102237A4 (en) Recombinant human factor ix and use thereof
IL197917A0 (en) Genetic incorporation of unnatural amino acids into proteins in mammalian cells
EP1758617A4 (en) Stable liquid and lyophilized formulation of proteins
EP2234636A4 (en) Stabilized formulations of peptides and proteins
EP2043677A4 (en) Combinations of human proteins to enhance viability of stem cells and progenitor cells
EP2297331A4 (en) Methods and compositions for production of recombinant protein in hbx-expressing mammalian cells
IL207174A (en) Isolated peptide capable of stimulating production of one or more extracelluar matrix proteins in fibroblast cells, a pharmaceutical composition comprising same and uses thereof
AU2003275326A8 (en) In vitro culture of tissue structures
GB2442271B (en) An in vitro human skin assay protocol which directly uses the natural cellular interactions between un-manipulated autologous human epidermal and dermal cells
IL188824A (en) Plant cells expressing recombinant human glucocerebrosidase and therapeutic uses thereof
AU2004906554A0 (en) Derivation and culture of human embryo-derived cells
HK1120523A (en) Methods of preparation of recombinant forms of human beta-amyloid protein and uses of these proteins
AU2006901819A0 (en) In VIVO stimulation of cellular material
AU2005904150A0 (en) Delivery of proteins and peptides
IL192438A0 (en) Stable enzymatic preparations and methods of use thereof
AU2006901822A0 (en) In vitro stimulation of cellular materials
IL201676A0 (en) Oral delivery of proteins and peptides

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed